International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-6 doi: 10.5281/zenodo.10416758
Original Article
Profile of Haematological Parameters in COVID-19 Positive Cases -A Cross Sectional Study
 ,
 ,
Published
Dec. 18, 2023
Abstract

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), a fast spreading and disastrous global pandemic. We have studied changes in haematology parameters in COVID-19 infected patients.

Objective/Aim: To assess haematological Parameters in COVID positive cases and analyse difference in profile of haematological parameters between categories of COVID positive cases.

Methods: This is a laboratory observation retrospective study. All COVID RT-PCR (Real Time Polymerase Chain Reaction) Positive cases from June 2020toMay 2022was considered for the study. The haematology parameters of cases including blood group and ESR were captured from hospital records and analysed for the difference between mild (Category A), moderate (Category B) and severe cases (Category C). Statistical analysis was done using SPSS software version 22. p value less than 0.05 was considered statistically significant.

Results: Total WBC count, absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute eosinophil count (AEC), absolute monocyte count (AMC), platelet count, neutrophil lymphocyte ratio (NLR), monocyte lymphocyte ratio (MLR), eosinophil lymphocyte ratio (ELR) and platelet lymphocyte ratio (PLR) between the three categories of cases were statistically significant. The commonest blood group was O positive and majority of O positive cases were in Category C. 81.9% cases tested for ESR showed raised ESR.

Conclusion: Haematology parameters can be considered to predict progression of the disease and assess prognosis in COVID-19 infection. Total WBC count, ANC, ALC, AEC, AMC, platelet count, NLR, MLR, ELR and PLR can be considered while monitoring COVID-19 cases.

Recommended Articles
Loading Image...
Volume-4, Issue-6
Citations
2786 Views
367 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved